AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26840703
Drug: Intracutaneous isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracutaneous isotonic saline injections (placebo treatment)
Trial: 22742888
Drug: Vision restoration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision restoration therapy
Trial: 12558088
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral slow-release tramadol
Trial: 10217370
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g aged garlic extract (AGE)
Trial: 10217370
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g DL‐alpha‐tocopherol acetate
Trial: 10217370
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g raw garlic
Trial: 7038316
Drug: Low-dose verapamil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose verapamil (0.075 mg/kg)
Trial: 7038316
Drug: Standard-dose verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose verapamil (0.15 mg/kg)
Trial: 7038316
Drug: Verapamil (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (low-dose and standard-dose)
Trial: 31630358
Drug: TAT-SOD (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAT-SOD (0.2 mL of 3000 U/mL TAT-SOD cream) applied topically at acupoint ST 36 once a day for 15 days
Trial: 31630358
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied topically at acupoint ST 36 once a day for 15 days
Trial: 22541893
Drug: Trabectedin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin plus pegylated liposomal doxorubicin (PLD) 30 mg/m² IV followed by a 3-h infusion of trabectedin 1.1 mg/m² every 3 weeks
Trial: 22541893
Drug: PLD 50
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 50 mg/m² every 4 weeks
Trial: 18018769
Drug: 16 SU
RxNorm normalized name: FLUCELVAX 2015-2016 Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 SU inactivated SARS-CoV vaccine
Trial: 18018769
Drug: 32 SU
RxNorm normalized name: ZINC OXIDE 25 g in 100 g TOPICAL CREAM [Erins Faces Mineral SPF 32 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 SU inactivated SARS-CoV vaccine
Trial: 9920144
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (gemfibrozil + lovastatin)
Trial: 7501353
Drug: Antenatal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal vitamin K and phenobarbital therapy
Trial: 2253912
Drug: Olsalazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (1 g twice daily)
Trial: 2253912
Drug: Pentasa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa (750 + 500 + 750 mg daily)
Trial: 2253912
Drug: Salofalk (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salofalk (750 + 500 + 750 mg daily)
Trial: 26226884
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 and 10 mg)
Trial: 19848610
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive sulfadoxine-pyrimethamine treatment
Trial: 17447832
Drug: Pramipexole 0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.125, 0.25, 0.50 or 0.75 mg once daily for 3 weeks
Trial: 17447832
Drug: Pramipexole at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole at a median dosage of 0.35 mg/day for 6 weeks
Trial: 17447832
Drug: Pramipexole after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole after 6 months' therapy
Trial: 7820492
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with glutamine supplementation (20 g/day for 3 days)
Trial: 7820492
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition without glutamine supplementation
Trial: 2205135
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam 0.33 mg.kg‐1
Trial: 2205135
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) 0.04 ml.kg‐1
Trial: 282538
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic energy therapy
Trial: 26485404
Drug: Guanidinoacetic acid
RxNorm normalized name: Guanidinoacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanidinoacetic acid (GAA) 3 g/day for 2 weeks
Trial: 23410999
Drug: 4-drug fixed-dose
RxNorm normalized name: 4-MIXED TRACE ELEMENTS INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug fixed-dose combination (FDC) of rifampicin, isoniazid, ethambutol, and pyrazinamide
Trial: 23410999
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations of rifampicin, isoniazid, ethambutol, and pyrazinamide
Trial: 21422411
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with full-dose anticoagulation
Trial: 14764774
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg/d)
Trial: 7946871
Drug: Propofol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (10 mg bolus followed by 30 mg/24 h infusion)
Trial: 2519671
Drug: Permethrin-treated bednets
RxNorm normalized name: Permethrin
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permethrin-treated bednets (500 mg/m2)
Trial: 31112621
Drug: I-neb (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-neb (75 mg tobramycin inhalation solution)
Trial: 31112621
Drug: PARI-LC Plus
RxNorm normalized name: formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PARI-LC Plus (300 mg tobramycin inhalation solution)
Trial: 16809994
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg intravenous bolus)
Trial: 16809994
Drug: Naloxone (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2-4 mg given over 30 min)
Trial: 16809994
Drug: Naloxone (2-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2-3 mg bolus followed by continuous infusion of 4 mg/h)
Trial: 16809994
Drug: Naloxone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (5 mg or greater)
Trial: 10836723
Drug: Basal urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal urinary excretion of cGMP in highly trained runners, sedentary subjects, and CAD patients
Trial: 9180622
Drug: Placebo biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo biofeedback treatment
Trial: 2579879
Drug: Oral propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propafenone 300 mg t.i.d.
Trial: 2579879
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone 1.5 mg/kg in three minutes.
Trial: 30690595
Drug: Lung lavage
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung lavage with diluted porcine surfactant (30 ml/kg)
Trial: 30690595
Drug: Bolus surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus surfactant (100 mg/kg)
Trial: 24755958
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg/d) in combination with docetaxel (75 mg/m2)
Trial: 10474062
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of DUP 996
Trial: 10474062
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of DUP 996
Trial: 10474062
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of DUP 996
Trial: 28325960
Drug: Paracetamol-Codeine (analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol-Codeine (analgesic group)
Trial: 26747845
Drug: W +
RxNorm normalized name: Culturelle Baby Grow + Thrive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: W + 2 day live TF‐CBT workshop + twice monthly phone consultation (W + L)
Trial: 22971521
Drug: 6 repeat
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 repeat intradermal injections of grass pollen extract (7 ng of Phl p 5 per injection) at 2-week intervals
Trial: 22971521
Drug: 2 intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 intradermal injections separated by 10 weeks
Trial: 22971521
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intradermal injection at 10 weeks
Trial: 19397752
Drug: i.v. dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. dexamethasone (0.5 mg/kg)
Trial: 15179544
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day, orally)
Trial: 11251702
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous magnesium sulfate
Trial: 11251702
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.9% saline (placebo)
Trial: 11251702
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous magnesium sulfate (after placebo)
Trial: 28655036
Drug: Simultaneous BiCIs
RxNorm normalized name: bicisate
DrugBank: Bicisate (DB11164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous BiCIs (2 cochlear implants during 1 surgical procedure)
Trial: 28655036
Drug: Sequential BiCIs
RxNorm normalized name: bicisate
DrugBank: Bicisate (DB11164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential BiCIs (2 cochlear implants with an interval of 2 years between implants)
Trial: 23989945
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment (home and GP)
Trial: 23989945
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment locations
Trial: 21928195
Drug: Thrombin bolus
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin bolus injection
Trial: 21928195
Drug: Thrombin slow
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin slow injection
Trial: 3552845
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg x 2)
Trial: 3552845
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg x 2)
Trial: 29809161
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel plus good wound care (BGWC)
Trial: 29809161
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel plus good wound care (control)
Trial: 24423298
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of pegvisomant
Trial: 23539702
Drug: Active intense
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intense pulsed light (IPL) treatment
Trial: 23539702
Drug: Placebo IPL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IPL treatment
Trial: 17764767
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) group (10^8 cells)
Trial: 17764767
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) group (10^7 cells)
Trial: 12552359
Drug: Modafinil 300
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 300 mg
Trial: 12552359
Drug: d-Amphetamine 20
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine 20 mg
Trial: 10986991
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special treatment
Trial: 27296693
Drug: rTSST-1v (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTSST-1v (100 ng to 30 μg)
Trial: 27296693
Drug: Al(OH)3 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al(OH)3 (200 μg, 600 μg, or 1 mg)
Trial: 20395895
Drug: 0 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mL saline
Trial: 20395895
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL saline
Trial: 20395895
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL saline
Trial: 20395895
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL saline
Trial: 18304239
Drug: Tooth Mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth Mousse containing CPP-ACP as a topical coating - Group D
Trial: 18304239
Drug: Tooth Mousse
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth Mousse containing CPP-ACP as a topical coating after fluoridated toothpaste - Group E
Trial: 16253978
Drug: OC-scheduled GnRH
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-scheduled GnRH antagonist (ganirelix)
Trial: 16253978
Drug: Non-scheduled GnRH
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-scheduled GnRH antagonist
Trial: 12108857
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg, twice daily via Turbuhaler
Trial: 1967210
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug plus weight loss groups
Trial: 366719
Drug: Aspirin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (5 grain ASA capsules)
Trial: 25823275
Drug: Umifenovir 200
RxNorm normalized name: umifenovir
DrugBank: Umifenovir (DB13609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umifenovir 200 mg four times daily for 5 days
Trial: 24055306
Drug: Fluzone(®) Intradermal
RxNorm normalized name: Fluzone 2018-2019
DrugBank: Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) (DB14454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone(®) Intradermal vaccine
Trial: 24055306
Drug: Fluzone(®) Intramuscular
RxNorm normalized name: Fluzone 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzone(®) Intramuscular vaccine
Trial: 21865396
Drug: H5N1 VLP
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1 VLP vaccine at 15, 45, or 90 μg HA/dose
Trial: 1644089
Drug: Captopril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (up to 150 mg/day for 6 weeks)
Trial: 6084121
Drug: Guanabenz 16
RxNorm normalized name: guanabenz 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz 16 mg
Trial: 6084121
Drug: Guanabenz (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz (2 to 32 mg)
Trial: 6084121
Drug: Guanabenz 16
RxNorm normalized name: guanabenz 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz 16 mg (sublingual and oral)
Trial: 31555926
Drug: 10-day normobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day normobaric hypoxic confinement (FiO2=0.14) with daily 90-min normoxic controlled hyperthermia (target rectal temperature: 38.5 °C)
Trial: 29969301
Drug: L-ornithine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine (400 mg)
Trial: 23149929
Drug: Mirabegron 200
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 200 mg
Trial: 20336066
Drug: Aleglitazar (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleglitazar (doses >300 microg)
Trial: 15826316
Drug: 5-Fluorouracil; Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation, followed by continuous 5-FU infusions for two more cycles.
Trial: 15826316
Drug: 5-FU with
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU with intravenous bolus injections of folinic acid on 5 consecutive days every 28 days for 6 cycles.
Trial: 1963274
Drug: Pirarubicin 20
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin 20 mg/m2
Trial: 1963274
Drug: Pirarubicin 24
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin 24 mg/m2
Trial: 1963274
Drug: Pirarubicin 25
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin 25 mg/m2
Trial: 1963274
Drug: Pirarubicin 27
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin 27 mg/m2
Trial: 1963274
Drug: Pirarubicin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin (all doses)
Trial: 24495883
Drug: Intracoronary melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary melatonin administration
Trial: 23277643
Drug: Oridermyl (acaricidal/antibiotic/
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oridermyl (acaricidal/antibiotic/ antifungal/anti‐inflammatory ointment), treated once daily for 10 days
Trial: 21049628
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: Tpanax Notoginseng Pills PO, Lornoxicam For Injection, 8 mg IM
Trial: 21049628
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: Tpanax Notoginseng Pills PO, Tong Mai Decoctions 200 mL PO
Trial: 21049628
Drug: Group IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV: Tpanax Notoginseng Pills PO, Lornoxicam For Injection 8 mg IM, Tong Mai Decoctions 200 mL PO
Trial: 21049628
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: Tpanax Notoginseng Pills PO
Trial: 16945983
Drug: Multi-component educational
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component educational intervention delivered by health personnel as part of usual care; details on dosage and duration not specified.
Trial: 16945983
Drug: Existing nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing nutrition education (control group); details on dosage and duration not specified.
Trial: 17877120
Drug: Carvedilol (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5 mg/day, 25 mg/day, 50 mg/day) administered in increasing doses every four weeks
Trial: 10522506
Drug: Oxymetazoline hydrochloride
RxNorm normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline hydrochloride (0.5 mg/mL) nasal spray containing benzalkonium chloride (0.1 mg/mL)
Trial: 1971461
Drug: Benzyl-1 isoquinoline
RxNorm normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzyl-1 isoquinoline derivative (458 L)
Trial: 7027062
Drug: 1 alpha-hydroxycholecalciferol
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha-hydroxycholecalciferol (2 micrograms daily for 3 months, then 1 microgram daily for 9 months)
Trial: 21270743
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) as preexposure prophylaxis (PrEP)
Trial: 19246334
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg/d (RSV10 group)
Trial: 19246334
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg/d (RSV20 group)
Trial: 17454156
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily from cycle day 3 to day 7
Trial: 17454156
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 100 mg daily from cycle day 3 to day 7
Trial: 15114429
Drug: 75 micro
RxNorm normalized name: Norgestrel 75 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 micro g midazolam
Trial: 15114429
Drug: ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole (200 mg b.i.d.)
Trial: 15114429
Drug: rifampicin (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampicin (450 mg q.d.)